Lung disease/pneumonitis in a patient with ulcerative colitis due to mesalazine
- 作者: Sablin O.1, Chernousova V.1, Komlev A.1
-
隶属关系:
- Nikiforov Russian Center of Emergency and Radiation Medicine
- 期: 卷 93, 编号 2 (2021)
- 页面: 199-203
- 栏目: Clinical notes
- URL: https://journals.rcsi.science/0040-3660/article/view/64727
- DOI: https://doi.org/10.26442/00403660.2021.02.200618
- ID: 64727
如何引用文章
全文:
详细
Mesalazine is a main medicine for treatment of ulcerative colitis. Most patience of left-sides and total colitis receive oral mesalazine for many years. Currently, there is a little information about the tolerability and safety of long-term use of mesalazine. The eosinophilic pneumonia, organizing pneumonia, and nonspecific interstitial pneumonia are very rare adverse effects of ulcerative colitis treatment with mesalazine. The article presents case of the development interstitial lung disease induced by mesalazine under long-term maintenance treatment for three years in the young patient with ulcerative colitis. It shows the difficulties in diagnosing this disease due to the work-long low-grade fever in manifestation of pneumonitis, the similarity of clinical and radiological manifestations (diffuse bilateral pattern in chest imaging). The article demonstrates the limitations of modern laboratory and instrumental diagnostic methods for the differentiation of disseminated lesions of the lung tissue, and shows the importance of elimination treatment of mesalazine-induced pneumonitis.
作者简介
O. Sablin
Nikiforov Russian Center of Emergency and Radiation Medicine
Email: vervlaber@gmail.com
ORCID iD: 0000-0002-2597-1220
д.м.н., проф., зав. клиническим отд. терапии и профпатологии
俄罗斯联邦, Saint PetersburgV. Chernousova
Nikiforov Russian Center of Emergency and Radiation Medicine
编辑信件的主要联系方式.
Email: vervlaber@gmail.com
ORCID iD: 0000-0002-6798-1857
врач-терапевт отд-ния терапии клинического отд. терапии и профпатологии
俄罗斯联邦, Saint PetersburgA. Komlev
Nikiforov Russian Center of Emergency and Radiation Medicine
Email: vervlaber@gmail.com
ORCID iD: 0000-0002-6929-4073
к.м.н., доц., зав. клиническим отд. пульмонологии и аллергологии
Saint Petersburg参考
- Халиф И.Л., Шапина М.В., Головенко А.О. и др. Течение хронических воспалительных заболеваний кишечника и методы их лечения, применяемые в Российской Федерации (Результаты многоцентрового популяционного одномоментного наблюдательного исследования). Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2018;28(3):54-62 [Khalif L, Shapina MV, Golovenko AO, et al. Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(3):54-62 (In Russ.)]. doi: 10.22416/1382-4376-2018-28-3-54-62
- Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current. J Crohn’s Colitis. 2012 Dec;6(10):991-1030. doi: 10.1016/j.crohns.2012.09.002
- Cosnes J, Gower-Rousseau C, Seksik P, Cortot A Epidemiology and natural history of inflammatory bowel disease. Gastroenterology. 2011 May;140(6):1785-94. doi: 10.1053/j.gastro.2011.01.055
- Burisch J, Pedersen N, Cukovic-Cavka S, et al. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe – an ECCO-EpiCom study. J Crohn’s Colitis. 2014 Jul;8(7):607-16. doi: 10.1016/j.crohns.2013.11.021
- Camus P, Rosenow EC. Drug-induced and iatrogenic respiratory disease London MPG Books. 2010.
- Burisch J, Pedersen N, Cukovic-Cavka S, et al. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe – an ECCO-EpiCom study. J Crohn’s Colitis. 2014 Jul;8(7):607-16. doi: 10.1016/j.crohns.2013.11.021
- Camus P, Fanton A, Bonniaud P, et al. Interstitial Lung Disease Induced by Drugs and Radiation. Respiration. 2004 Jul-Aug;71(4):301-26. doi: 10.1159/000079633
- Kotsiou OS, Konstantinos I. Gourgoulianis. A case report of mesalazine-induced lung injury: A reversible drug side effect. Respir Med Case Rep. 2019 May 27;27:100865. doi: 10.1016/j.rmcr.2019.100865
- Moeser A, Pletz MW, Hagel S, et al. Lung disease and ulcerative colitis – mesalazine-induced bronchiolitis obliterans with organizing pneumonia or pulmonary manifestation of inflammatory bowel disease? Gastroenterol. 2015 Sep;53(9):1091-8. doi: 10.1055/s-0041-103377
- Ankit Gupta and Swati Gulati. Mesalamine induced eosinophilic pneumonia. Respir Med Case Rep. 2017 Apr 12. doi: 10.1016/j.rmcr.2017.04.010
- Hao Ding, Xiao-Chang Liu, Qiao Mei, et al. Ulcerativa colitis flair induced by mesalazine suppositories hypersensitivity. World J Gastroenterol. 2014 Apr 7. doi: 10.3748/wjg.v20.i13.3716
- Kim JH, Lee JH, Koh ES, et al. Acute eosinophilic pneumonia related to mesalazine suppository. Asia Pac Allergy 2013 Apr;3(2):136-9. doi: 10.5415/apallergy.2013.3.2.136
- Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest. 2007 Feb;131(2):524-32. doi: 10.1378/chest.06-1074
- Zhao Y, Wang J, Liu Z, et al. Pulmonary dysfunction in 114 patients with inflammatory bowel disease. Medicine (Baltimore). 2017 May;96(18):e6808. doi: 10.1097/MD.0000000000006808
- Макарчук П.А., Бриткина О.С., Белоусова Е.А. Будесонид ММХ в лечении язвенного колита. Реальная клиническая практика. Альманах клин. медицины. 2019;47(6):505-10 [Makarchuk PA, Britkina OS, Belousova EA. Budesonide ММХ in the treatment of ulcerative colitis: real world clinical practice. Almanac of Clinical Medicine. 2019;47(6):505-10 (In Russ.)]. doi: 10.18786/2072-0505-2019-47-064
- Po-Han Huang, Chia-Jung Kuo, Cheng-Tang Chiu. Mesalazine-related lung disease in a patient with ulcerative colitis: A case report. Medicine (Baltimore). 2018 Nov;97(48):e13242. doi: 10.1097/MD.0000000000013242